Together, these data show that in CRISPRKMT2A::AFF1 ALL, CD133+ blasts are enriched for a stem cell-like signature and possess almost all the proliferative potential of the leukemia. This evidence concerns the gene PROM1 and acute lymphoblastic leukemia.